Introduction
============

Chronic hepatitis C virus (HCV) infection affects 3% of the world's population and 1.3% of the United States' population.[@b1-mjhid-9-1-e2017019],[@b2-mjhid-9-1-e2017019] It is a leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma, and is one of the most common causes of liver transplants in the United States.[@b2-mjhid-9-1-e2017019] Besides hepatic complications, chronic HCV infection is also associated with several extra-hepatic manifestations including thrombocytopenia. Thrombocytopenia in chronic HCV infection is a major problem, particularly in patients with advanced liver disease. The risk of serious bleeding with severe thrombocytopenia can prevent invasive procedures including biopsies for staging.[@b3-mjhid-9-1-e2017019] Thrombocytopenia can also complicate bleeding manifestations such as variceal bleeding. It may impede the initiation and continuation of antiviral therapy, potentially decreasing the probability of successful HCV treatment.[@b4-mjhid-9-1-e2017019] Recent studies have evaluated the underlying mechanism of thrombocytopenia in chronic HCV infection and assessed the usefulness of several therapeutic options.

Epidemiology
============

The prevalence and degree of thrombocytopenia increase with the severity of liver disease and correlates to hepatocellular damage and hepatic fibrosis.[@b5-mjhid-9-1-e2017019] However, use of varying definition for thrombocytopenia and insufficient data on study characteristics such as age, gender, HCV treatment rates and disease severity preclude a more accurate estimate of the overall prevalence.[@b6-mjhid-9-1-e2017019] A systematic review estimated the average prevalence of thrombocytopenia in chronic HCV infection to be nearly 24% ([Table 1](#t1-mjhid-9-1-e2017019){ref-type="table"}).[@b6-mjhid-9-1-e2017019]

Mechanism
=========

The pathophysiology of thrombocytopenia in patients with HCV infection is thought to be multifactorial. Besides inducing an autoimmune reaction with production of anti-platelet antibodies, the virus also causes direct bone marrow suppression with resulting thrombocytopenia.[@b7-mjhid-9-1-e2017019]--[@b10-mjhid-9-1-e2017019] Chronic HCV infection induced liver fibrosis and cirrhosis leads to portal hypertension with subsequent hypersplenism and sequestration of platelets, decreased the production of thrombopoeitin, and endothelial dysfunction, all of which can contribute to thrombocytopenia.[@b11-mjhid-9-1-e2017019]--[@b14-mjhid-9-1-e2017019] Although uncommonly used in developed countries, interferon (IFN) and ribavirin used as part of anti-HCV therapy can also contribute to low platelet count.[@b15-mjhid-9-1-e2017019]

Impact on Clinical Management
=============================

Although thrombocytopenia in chronic HCV infection is typically low grade and not life-threatening, it represents an obstacle to different diagnostic or therapeutic modalities and may preclude the use of anti-viral treatment.

The greatest challenge in the care of chronic HCV patients with thrombocytopenia is the difficulty in initiating or maintaining IFN containing anti-viral therapy. Although this challenge can be avoided with the use of sole DAAs as the primary treatment modality, thrombocytopenia remains of particular interest, especially in cases of advanced liver disease. In a study by Wang et al., baseline thrombocytopenia increased the risk of drug cessation. Patients with baseline thrombocytopenia actually exhibited compromised sustained virologic response (SVR) rates while those with acquired thrombocytopenia did not. Thus, use of growth factors to maintain SVR rate would be beneficial in those with baseline thrombocytopenia rather than in those who acquire it during therapy as dose reduction doesn't decrease SVR in such cases.[@b16-mjhid-9-1-e2017019]

Thrombocytopenia in HCV may also be a problem for patients with baseline platelet count of \<50.000/mm^3^, particularly in the presence of previous bleeding even when they are treated with DAAs. However, patients with thrombocytopenia and fibrosis have attained \>90% SVR with DAAs even if in a proportion lower in respect to patients with a normal platelet count. Thus, DAAs may be continued most of the times without interruption and thrombopoietin mimetics would be helpful only with severe thrombocytopenia (such as a platelet count of \<25,000/mm^3^).[@b17-mjhid-9-1-e2017019]--[@b19-mjhid-9-1-e2017019]

Directly-acting antivirals (DAAs)
---------------------------------

Recently updated World Health Organization guidelines recommend that DAA regimens (including simeprivir, grazoprevir, daclatasvir, ledipasvir, and sofosbuvir) be used for the treatment of persons with hepatitis C infection rather than regimens with pegylated interferon and ribavirin.[@b16-mjhid-9-1-e2017019] Combinations of 2 or 3 DAAs have been shown to be highly effective and safe in both cirrhotic and non-cirrhotic patients in different phase III clinical trials and large real life cohorts with providing SVR rates of \>95%. While headache, diarrhea, fatigue, and nausea have frequently been observed, hematologic abnormalities including thrombocytopenia were reported in no more than 1% of cases.[@b17-mjhid-9-1-e2017019],[@b18-mjhid-9-1-e2017019] Lee et al. reported that DAA therapy in one patient precipitated ITP refractory to various treatment modalities and it required several weeks of therapy with multiple platelet transfusions, intravenous immunoglobulin, steroids and romiplostim to achieve a stable platelet count of 40,000/mm^3^ with no signs of bleeding.[@b19-mjhid-9-1-e2017019] However, this is only one case describing any relation of DAA with thrombocytopenia. A study by Forns et al. showed that HCV genotype 1a-infected patients with surrogate markers of portal hypertension or impaired liver function such as thrombocytopenia and hypoalbuminemia at baseline achieved high SVR rates with ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin and treatment was well tolerated.[@b20-mjhid-9-1-e2017019] Additionally, reduction in liver fibrosis markers such as fibrosis-4 score and aspartate transaminase platelet ratio along with regression of transient elastography have been reported with use of DAAs in chronic hepatitis C.[@b21-mjhid-9-1-e2017019] In any case, by the time, thrombocytopenia improves following SVR obtained with any antiviral therapy among chronic HCV infected patients with advanced hepatic fibrosis.[@b21-mjhid-9-1-e2017019],[@b22-mjhid-9-1-e2017019]

INF based antiviral therapy
---------------------------

Although IFN based antiviral therapy is uncommonly used in developed countries nowadays, the prohibitive cost of DAA may require the use of INF based therapy along with the addition of thrombopoietin mimetics, if required, in economically disadvantaged areas. Additionally, in chronic hepatitis C cases treated with pegylated INF plus ribavirin, single nucleotide polymorphisms at or near the IL-28B gene have been shown to be a predictor of SVR.[@b23-mjhid-9-1-e2017019],[@b24-mjhid-9-1-e2017019] The American Gastroenterological Association recommends dose reduction of INF with a platelet count between 25,000--50,000 and withdrawal of INF-based treatment with a count below 25,000.[@b25-mjhid-9-1-e2017019] This is important because the antiviral therapy itself may cause a further drop in platelet count.[@b26-mjhid-9-1-e2017019] Studies have shown IFN-based therapy to cause severe thrombocytopenia in up to 13% of patients, with the incidence higher in patients with lower baseline platelet count.[@b27-mjhid-9-1-e2017019],[@b28-mjhid-9-1-e2017019] The modifications in IFN-based therapy have potential to lower the chances of attaining SVR. The increased risk of bleeding may also impede the initiation and maintenance of different invasive diagnostic and therapeutic procedures such as liver biopsy, variceal banding, paracentesis and thoracentesis, central line insertion, endoscopy and elective surgery.

Management
==========

Various pharmacological and non-pharmacological therapeutic options are available for the management of thrombocytopenia in chronic HCV infection ([Table 2](#t2-mjhid-9-1-e2017019){ref-type="table"}). These treatment modalities vary in their effectiveness and adverse effect profiles. The most practical strategy in treating HCV-related thrombocytopenia is based on the principle that eradication of HCV infection may result in remission of thrombocytopenia. By eradicating HC virus, DAAs are supposed to improve thrombocytopenia related to hepatitis C infection but may not ameliorate thrombocytopenia related to cirrhosis or portal hypertension. In cases of IFN based antiviral therapy, the usual approach is to continue with the therapy, reducing the dose if platelet count drops below 50,000 cells/μL or discontinuing it for a platelet count of below 25,000 cells/μL.[@b25-mjhid-9-1-e2017019] The measures described below are mostly supportive. As expected, there is a lot of published data on how these measures might be necessary to IFN-based therapy but not to them with DAAs.

Platelet transfusion
--------------------

Though widely used for the management of thrombocytopenia, platelet transfusion has several limitations, especially in patients with chronic liver disease. The increase in platelet count is transient, and hence useful only for procedures or during bleeding. Patients are also at risk for transfusion-related complications, which can occur in up to 30% of the recipients and include viral or bacterial infection, febrile non-hemolytic reactions, and iron overload.[@b29-mjhid-9-1-e2017019] Nearly half of all patients undergoing multiple platelet transfusions can develop platelet refractoriness secondary to human leukocyte antigen (HLA) alloimmunization.[@b30-mjhid-9-1-e2017019],[@b31-mjhid-9-1-e2017019] It may not always ensure maintenance of homeostatic platelet levels.[@b32-mjhid-9-1-e2017019] Besides, the requirement of hospitalization and high cost may be prohibitive in a resource-poor setting.

Splenectomy and splenic artery embolization
-------------------------------------------

Splenectomy and splenic artery embolization have been used to correct thrombocytopenia in patients with hypersplenism, producing significant and persistent increases in platelet count.[@b33-mjhid-9-1-e2017019],[@b34-mjhid-9-1-e2017019] Akahoshi et al. studied the effect of splenectomy in patients with HCV-associated thrombocytopenia and found above 200% rise in mean platelet count at 1 month after splenectomy.[@b35-mjhid-9-1-e2017019] In cases of IFN-based antiviral therapy, the positive effect is known to persist even after the initiation of antiviral therapy, with the mean platelet count nearly 80% above baseline after 12 months of the therapy. Splenectomy, however, is an invasive procedure with high risk of bleeding, sepsis and portal vein thrombosis. Asplenic patients are susceptible to overwhelming post-splenectomy infection. Splenic artery embolization may be an alternative option. In a study by Barcena et al., the mean platelet count increased by 342% from the baseline after 12 weeks of partial splenic artery embolization.[@b36-mjhid-9-1-e2017019] Splenic artery embolization, though associated with lower morbidity and mortality than splenectomy, is not free of complications.

Pharmacotherapy
---------------

### Steroids

With HCV reported to play a pathogenic role in some cases of immune thrombocytopenic purpura, there have been case reports of significant improvement in HCV-related thrombocytopenia with the use of corticosteroid.[@b37-mjhid-9-1-e2017019] As described earlier, Lee et al. described a case of resistant ITP which developed after DAA therapy and did not respond to high dose prednisone.[@b20-mjhid-9-1-e2017019] Lebano et al. reported a case where the platelet count increased by 175% from baseline six months after steroid therapy and improved further (360% above baseline) after another six months of IFN and ribavirin.[@b37-mjhid-9-1-e2017019] Despite similar reports of steroids causing a variable rise in platelet counts, they are not routinely considered in the management of thrombocytopenia in HCV infection because of the possible risk of worsening viral loads and liver damage.[@b38-mjhid-9-1-e2017019],[@b39-mjhid-9-1-e2017019]

### Thrombopoietin analogue

Thrombopoietin (TPO) is a cytokine predominantly synthesized by the hepatocytes in the liver and plays a central role in thrombopoiesis. It binds to TPO receptors (mpl) expressed on the surface of megakaryocyte precursor cells and megakaryocytes, activating signal transduction cascades that result in proliferation and maturation of megakaryocytes.[@b40-mjhid-9-1-e2017019] A better understanding of TPO and its role in platelet production and function has led to newer treatment modalities. Synthetic thrombopoietins such as recombinant human TPO and pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMDGF) cause an increase in platelet count.[@b41-mjhid-9-1-e2017019],[@b42-mjhid-9-1-e2017019] However, their use has been hampered by the appearance of neutralizing antibodies that cross-reacts with both recombinant and endogenous TPO.[@b43-mjhid-9-1-e2017019] In a study using PEG-rHuMDGF injection by Li et al., an initial rise in platelet count was followed by the development of an antibody against TPO, detected as early as 56 days after the initial injection.[@b44-mjhid-9-1-e2017019] This was associated with corresponding fall in platelet count and a marked decrease in bone marrow megakaryocytes, with an average nadir platelet count of 6% to 8% of baseline.

Thrombopoietin-mimetic agents, in particular, eltrombopag and romiplostim, have been shown to increase platelet count without eliciting any immunogenicity.[@b45-mjhid-9-1-e2017019]--[@b47-mjhid-9-1-e2017019] Romiplostin is a peptibody composed of four TPO mimetic peptides attached by glycine bridges to the heavy chain portion of immunoglobulin G. It acts by dimerizing the TPO receptor via its paired peptides, which stimulates platelet production.[@b48-mjhid-9-1-e2017019] It is given by weekly subcutaneous injections. Various clinical trials in patients with chronic immune thrombocytopenic purpura have shown romiplostin to cause a dose dependent increase in platelet count, resulting in lower rates of treatment failure, decreased the need for splenectomy and improved quality of life.[@b49-mjhid-9-1-e2017019]--[@b51-mjhid-9-1-e2017019] Lee et al. described romiplostim use in a case of resistant ITP after DAA therapy.[@b20-mjhid-9-1-e2017019] A study by Moussa et al. in 35 patients with chronic liver disease and thrombocytopenia secondary to HCV infection showed more than three-fold increase in mean platelet count from the baseline after 3 weeks of therapy.[@b52-mjhid-9-1-e2017019] And the mean platelet count remained 1.5 times above the baseline even after 2 months of stopping the drug. Similarly, Voican et al. reported two cases where romiplostin was used to control severe thrombocytopenia; this allowed anti-HCV treatment with pegylated-IFN and ribavirin to be completed successfully without any dose reduction or discontinuation.[@b53-mjhid-9-1-e2017019]

Eltrombopag, an orally active TPO agonist, interacts with the trans-membrane domain of the thrombopoietin receptor, activating JAK2/STAT signaling pathways and increasing proliferation and differentiation of human bone marrow progenitor cells into megakaryocytes.[@b54-mjhid-9-1-e2017019] Preclinical studies have shown the binding site on the receptor and the signal transduction mechanism to be different for eltrombopag as compared to thrombopoeitin, causing the two to have an additive effect on platelet production.[@b55-mjhid-9-1-e2017019] Eltrombopag has been found to be safe and effective in the management of HCV-related thrombocytopenia.[@b56-mjhid-9-1-e2017019],[@b57-mjhid-9-1-e2017019] In a phase II trial,[@b56-mjhid-9-1-e2017019] 71--91% of the patients receiving eltrombopag had a dose dependent increase in their platelet counts to levels which allowed initiation of antiviral therapy. 36--65% of patients in the eltrombopag group completed first 12 weeks of antiviral therapy compared to 6% in the placebo group. Though platelet counts decreased during the antiviral treatment phase despite the use of eltrombopag, the count consistently remained above baseline as well as above the level at which a reduction in the pegylated-IFN dose is recommended (\<50,000 per cubic millimeter). Another phase III trial, Eltrombopag to Initiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C-Related Liver Disease (ENABLE-1 and ENABLE-2), showed a higher rate of sustained virological response with the use of eltrombopag than placebo (23% vs. 14%, p = 0.0064 in ENABLE-1 and 19% vs. 13%, p = 0.0202 in ENABLE-2).[@b57-mjhid-9-1-e2017019] Pegylated-IFN was administered at higher doses, with fewer dose reductions in the eltrombopag group. Throughout the antiviral treatment, a platelet count of 50,0000 per cubic millimeter or higher was maintained in more patients receiving eltrombopag than placebo (69% vs. 15% in ENABLE-1 and 81% vs. 23% in ENABLE-2).

The most common side effect with these thrombopoietin-mimetic agents is a headache, with the reported incidence in clinical trials ranging from 7% to 21%.[@b49-mjhid-9-1-e2017019]--[@b51-mjhid-9-1-e2017019],[@b56-mjhid-9-1-e2017019],[@b57-mjhid-9-1-e2017019] Eltrombopag also commonly causes dry mouth, abdominal pain, and nausea, and may be associated with hepatic decompensation like ascites and hepatic encephalopathy.[@b56-mjhid-9-1-e2017019],[@b57-mjhid-9-1-e2017019] Romiplostin may be associated with increased deposition of reticulin in the bone marrow, and possibly marrow fibrosis.[@b58-mjhid-9-1-e2017019] The risk of thromboembolic events like portal vein thrombosis is seen with all these agents.[@b57-mjhid-9-1-e2017019],[@b58-mjhid-9-1-e2017019]

Other newer drugs currently under investigation include the peptidic compounds like AMG-531 and PEG-TPOmp, non-peptidic compound like AKR-501, and monoclonal antibodies. AMG-531, a TPO agonist, has been designed with no sequence homology to human TPO to reduce the likelihood of an anti-TPO immune response. Phase II and III studies in ITP patients have shown promising early results with a dose-dependent increase in platelet count with no serious adverse events.[@b59-mjhid-9-1-e2017019],[@b60-mjhid-9-1-e2017019] PEG-TPOmp is a pegylated TPO peptide agonist and has shown to be effective in animal studies. Similarly, AKR-501 is an orally active TPO agonist and has been shown to be effective in clinical studies involving healthy volunteers.[@b60-mjhid-9-1-e2017019] In vitro studies have shown engineered monoclonal antibodies to bind mpl and activate TPO-expressing cell lines.[@b61-mjhid-9-1-e2017019] However, all these compounds and drugs need further clinical studies, including in patients with HCV and chronic liver disease before they can be considered for routine use.

### Cytokines with thrombopoietic potential

Cytokine such as interleukin-11 (IL-11) has thrombopoietic activity. Recombinant human IL-11 (rhIL-11, Oprelvekin), approved for the management of chemotherapy-related thrombocytopenia, has also been shown to increase platelet count in chronic HCV infection.[@b62-mjhid-9-1-e2017019]--[@b64-mjhid-9-1-e2017019] In a study by Lawitz et al., use of rhIL-11 (Oprelvekin) in patients with advanced liver disease associated with chronic HCV infection caused a 38% increase in mean platelet count from baseline after 12 weeks of therapy, along with an improvement in the mean Knodell Histology Activity Index from 7.3 to 5.9 (p= 0.006).[@b65-mjhid-9-1-e2017019] However, the platelet level tends to fall back on discontinuing the drug.[@b62-mjhid-9-1-e2017019] It also causes fluid retention in most patients, and this can be a significant management problem in patients with decompensated cirrhosis.[@b64-mjhid-9-1-e2017019]

### Erythropoietin

The amino-terminal domain on TPO, which binds to thrombopoietin receptor shares significant homology with erythropoietin. Recombinant human erythropoietin (rhEPO) has shown promising results in improving thrombocytopenia in cirrhotic patients.[@b66-mjhid-9-1-e2017019],[@b67-mjhid-9-1-e2017019] Pirisi et al. studied the effect of rhEPO on the platelet count in 19 patients with thrombocytopenia related to chronic liver disease, and found an increase in mean platelet count by 45% from the baseline in the treatment group as compared to 0% in the placebo group (p \< 0.02).[@b67-mjhid-9-1-e2017019] As rhEPO has also been suggested for the treatment of ribavirin-induced anemia in patients with HCV, this provides the possibility of using a single drug for the treatment of both thrombocytopenia and anemia related to the INF-based antiviral therapy. However, further studies are needed to confirm this.

### Danazol

Danazole used in immune thrombocytopenic purpura may have a role in HCV-related thrombocytopenia. In a study by Alvarez et al., the use of danazol along with the anti-HCV treatment resulted in a 75% increase in the mean platelet count from the baseline and allowed 90% of the patients to complete their antiviral treatment.[@b68-mjhid-9-1-e2017019] Anemia, headache, arthralgia and myalgia were some of the common adverse effects of the combination therapy reported in the study.

### L-carnitine

L-carnitine is a nutrient synthesized from amino acids lysine and methionine. In a study, the addition of L-carnitine to pegylated-IFN-α plus ribavirin resulted in a decrease in the incidence of thrombocytopenia during antiviral therapy.[@b69-mjhid-9-1-e2017019]

Conclusions
===========

Thrombocytopenia in chronic HCV infection has a multifactorial pathophysiology and remains a major problem. The recent change in DAAs without IFN, as the frontline therapy for HCV, permit to avoid the dilemmas associated with initiating or maintaining IFN based anti-viral therapy.

DAAs, with high SVR and less than 1% of hematological adverse effects, have been shown to improve thrombocytopenia associated with HCV infection as well as advanced hepatic disease. While eradication of HCV infection itself is the most practical strategy for the remission of thrombocytopenia, various pharmacological and non-pharmacological therapeutic options, which vary in their effectiveness and adverse effect profiles, are available. Thrombopoietin-mimetic agents like eltrombopag and romiplostim have been shown to be safe and effective for HCV-related thrombocytopenia in various studies.

Studies of the long-term effects of DAA on extrahepatic consequences of HCV infection are in progress.
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###### 

Prevalence of thrombocytopenia in chronic hepatitis C infection.

  Author                                               Study Design      Total cases in study   Platelet counts (X 10^9^)   Cases with cirrhosis (%)   Cases receiving Anti-viral therapy (%)   Cases with thrombocytopenia (%)
  ---------------------------------------------------- ----------------- ---------------------- --------------------------- -------------------------- ---------------------------------------- ---------------------------------
  Ikeda et. al\[[@b70-mjhid-9-1-e2017019]\]            Cohort            1056                   140--150                    9.7                        8.2                                      38.7
  Moriyama et. al \[[@b71-mjhid-9-1-e2017019]\]        Cohort            645                    140--150                    NR                         0.0                                      29.2
  Nagamine et. al \[[@b72-mjhid-9-1-e2017019]\]        Cross-sectional   368                    140--150                    0.0                        NR                                       41.0
  Ordi-Ros et al. \[[@b73-mjhid-9-1-e2017019]\]        Cross-sectional   230                    140--150                    11                         8.3                                      18.3
  Poynard et al. \[[@b74-mjhid-9-1-e2017019]\]         Cross-sectional   1354                   140--150                    NR                         0.0                                      31.1
  Sylvestre et al. \[[@b75-mjhid-9-1-e2017019]\]       Cross-sectional   409                    140--150                    NR                         NR                                       31.1
  Shanmuganathan et al.\[[@b76-mjhid-9-1-e2017019]\]   Cross-sectional   182                    140--150                    9.9                        NR                                       28.0
  Taliani et al. \[[@b77-mjhid-9-1-e2017019]\]         Cross-sectional   78                     140--150                    48.7                       0.0                                      44.8
  Borroni et al. \[[@b78-mjhid-9-1-e2017019]\]         Cross-sectional   228                    130--140                    13.2                       0.0                                      9.6
  Dalekos et al. \[[@b79-mjhid-9-1-e2017019]\]         Cohort            75                     130--140                    NR                         NR                                       13.3
  Kaul et al. \[[@b80-mjhid-9-1-e2017019]\]            Cross-sectional   264                    130--140                    3.3                        Nr                                       28
  Luo et al. \[[@b81-mjhid-9-1-e2017019]\]             Cross-sectional   111                    130--140                    20.7                       NR                                       28.9
  Prieto et al. \[[@b82-mjhid-9-1-e2017019]\]          Cross-sectional   100                    130--140                    25                         16                                       45
  Romagnuolo et al. \[[@b83-mjhid-9-1-e2017019]\]      Cross-sectional   54                     130--140                    7.4                        0.0                                      24.1
  Zachou et al. \[[@b84-mjhid-9-1-e2017019]\]          Cohort            174                    130--140                    20.7                       30.0                                     31.2
  Hu et al. \[[@b85-mjhid-9-1-e2017019]\]              Cohort            112                    100--130                    100                        43.8                                     30.3
  Kim et al. \[[@b86-mjhid-9-1-e2017019]\]             Cross Sectional   141                    100--130                    7.4                        NR                                       24.8
  Renou et al. \[[@b87-mjhid-9-1-e2017019]\]           Cross Sectional   110                    100--130                    12.7                       0.0                                      18.2
  Cicardi et al. \[[@b88-mjhid-9-1-e2017019]\]         Cohort            360                    \<100                       24                         0.0                                      16.4
  Nahon et al. \[[@b89-mjhid-9-1-e2017019]\]           Cohort            97                     \<100                       100                        NR                                       45.4
  Wang et al. \[[@b90-mjhid-9-1-e2017019]\]            Cross Sectional   140                    \<100                       5.0                        NR                                       15.7

###### 

Management of hepatitis C-related thrombocytopenia.

  Author/Study                                           Year   No. of patients   Baseline platelet, mean or median (range)   Intervention                                       Mean/median platelet count after the intervention                                                          Major complications
  ------------------------------------------------------ ------ ----------------- ------------------------------------------- -------------------------------------------------- ---------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------
  Akahoshi et al. \[[@b35-mjhid-9-1-e2017019]\]          2011   100               56,000 (22,000 -- 75,000)                   Splenectomy followed by PEG-IFN+RBV                105,000 (range 40,000 -- 140,000) at 6 months                                                              Portal vein thrombosis (7%), Wound infection (4%), Bleeding (2%)
  Barcena et al. \[[@b36-mjhid-9-1-e2017019]\]           2005   3                 44,067 (39,900 -- 50,300)                   Partial splenic artery embolization                195,000 (128,000 -- 243,000) at 12 months                                                                  
  McHutchison et al. \[[@b56-mjhid-9-1-e2017019]\]       2007   74                55,000 (26,000 -- 94,000)                   PEG-IFN/Ribavirin plus Eltrombopag vs. placebo     Median increase of 31,000 or 54,000 (depending on the dose of Eltrombopag) vs. Median decrease of 25,000   Headache (21%), Dry mouth (11%) Abdominal pain (7%), Nausea (7%)
  Afdhal et al./ENABLE-1 \[[@b57-mjhid-9-1-e2017019]\]   2014   715               59,0000                                     PEG-IFN2a/Ribavirin plus Eltrombopag vs. placebo   86,000 vs. 40,000 at 45 weeks                                                                              Thrombo-embolic events (3% vs 1%); Hepatic decompensation (10% vs 5%)
  Afdhal et al./ENABLE-2 \[[@b57-mjhid-9-1-e2017019]\]   2014   805               59,000                                      PEG-IFN2b/Ribavirin plus Eltrombopag vs. placebo   105,000 vs. 55,000 at 45 weeks                                                                             Thrombo-embolic events (4% vs 0.4%); Hepatic decompensation (10 vs 5%)
  Moussa et al. \[[@b52-mjhid-9-1-e2017019]\]            2012   35                31,000 (21,000--46,000)                     Romiplostim                                        46,000 (range 26,000 --88,000) at 3 months (2 months after stopping treatment)                             
  Alvarez et al. \[[@b91-mjhid-9-1-e2017019]\]           2011   49                69,067 (34,000 -- 88,200)                   Danazol plus IFN plus Ribavirin                    121,081 (range 46,000 -- 216,000)                                                                          Anemia (40%), Headache (38%) Arthralgia (31%), Myalgia (31%) Malaise (29%), Nausea (26%), Hyposthenia (24%)
  Malaguarnera et al. \[[@b92-mjhid-9-1-e2017019]\]      2011   69                384,000 vs. 412,000                         PEG-IFN + RBV with or without L-carnitine          298,000 vs. 327,000 at 12 months                                                                           
  Lawitz et al. \[[@b65-mjhid-9-1-e2017019]\]            2004   20                143,000 (43,000 -- 244,000)                 Recombinant human IL-11 (Oprelvekin)               Median of 198,000 at 45 weeks                                                                              Edema of lower extremities (100%)
